Search research articles
Contact Us
Filters
Showing results (61-70 of 87) with videos related to
Page
of 9
Sort By:
ESMO Open
|
August 14, 2025
Addressing screening failures in early-phase clinical trials in oncology: impact on patient outcomes and strategies for improvement
I Korakis, K Ouali, B Hanvic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2011
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
J-C Soria, J Cortes, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
J-C Soria, J Cortes, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2015
Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?
S Postel-Vinay, Y Boursin, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
C Massard, J Mateo, Y Loriot, et al.
British Journal of Cancer
|
August 11, 2011
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
F Farace, C Massard, N Vimond, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
November 7, 2015
[Not Available]
C Dariane, C Pasqualini, N Gaspar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 31, 2018
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer
C Massard, A Azaro, J-C Soria, et al.
British Journal of Cancer
|
September 19, 2007
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
C Massard, J-J Voigt, A Laplanche, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 11, 2018
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours
H Herin, S Aspeslagh, E Castanon, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 87) with videos related to
Sort By:
Page
of 9
ESMO Open
|
August 14, 2025
Addressing screening failures in early-phase clinical trials in oncology: impact on patient outcomes and strategies for improvement
I Korakis, K Ouali, B Hanvic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2011
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
J-C Soria, J Cortes, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
J-C Soria, J Cortes, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2015
Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?
S Postel-Vinay, Y Boursin, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
C Massard, J Mateo, Y Loriot, et al.
British Journal of Cancer
|
August 11, 2011
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
F Farace, C Massard, N Vimond, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
November 7, 2015
[Not Available]
C Dariane, C Pasqualini, N Gaspar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 31, 2018
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer
C Massard, A Azaro, J-C Soria, et al.
British Journal of Cancer
|
September 19, 2007
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
C Massard, J-J Voigt, A Laplanche, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 11, 2018
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours
H Herin, S Aspeslagh, E Castanon, et al.
Page
of 9